Usefulness of the CHAMPS score for risk stratification in lower gastrointestinal bleeding

Munehiko Tajika1, Tamotsu Matsuhashi1, Yosuke Shimodaira1, Sho Fukuda1, Tsuyotoshi Tsuji2, Kae Sugawara2, Youhei Saruta2, Yasutaka Takahashi2, Kenta Watanabe1 & Katsunori Iijima1

We have recently developed a simple prediction score, the CHAMPS score, to predict in-hospital mortality in patients with upper gastrointestinal bleeding. In this study, the primary outcome of this study was the usefulness of the CHAMPS score for predicting in-hospital mortality with lower gastrointestinal bleeding (LGIB). Consecutive adult patients who were hospitalized with LGIB at two tertiary academic medical centers from 2015 to 2020 were retrospectively enrolled. The performance for predicting outcomes with CHAMPS score was assessed by a receiver operating characteristic curve analysis, and compared with four existing scores. In 387 patients enrolled in this study, 39 (10.1%) of whom died during the hospitalization. The CHAMPS score showed good performance in predicting in-hospital mortality in LGIB patients with an AUC (95% confidence interval) of 0.80 (0.73–0.87), which was significantly higher in comparison to the existing scores. The risk of in-hospital mortality as predicted by the CHAMPS score was shown: low risk (score ≤ 1), 1.8%; intermediate risk (score 2 or 3), 15.8%; and high risk (score ≥ 4), 37.1%. The CHAMPS score is useful for predicting in-hospital mortality in patients with LGIB.

Abbreviations
AUC  Area under the receiver operating characteristic curve
CI  Confidence interval
cRS  Clinical Rockall score
CT  Computer tomography
GBS  Glasgow-Blatchford score
GIB  Gastrointestinal bleeding
LGIB  Lower gastrointestinal bleeding
NPV  Negative predictive value
PPV  Positive predictive value
ROC  Receiver operating characteristic curve
UGIB  Upper gastrointestinal bleeding

Despite advances in endoscopic and radiologic techniques, gastrointestinal bleeding (GIB) is still associated with significant morbidity and mortality1,2. GIB is classified into upper gastrointestinal bleeding (UGIB) and lower gastrointestinal bleeding (LGIB) depending on the anatomic location of the bleeding source. Although there are some differences in the topical treatment (e.g., hemostasis through esophagogastrroduodenoscopy vs. colonoscopy, the need for a computed tomography (CT) examination at presentation, or the administration of proton pump inhibitors), other systemic treatments (e.g., blood transfusion, treatment for comorbidities or accompanying complicated diseases, etc.) are largely common, irrespective of the bleeding source. In addition, an accurate diagnosis of the location of bleeding cannot always be made, especially at the initial presentation.

Some risk stratification scores have been developed to predict a variety of clinically relevant outcomes for patients with GIB3–5; however, many of these are used to predict the need for hospitalization or the need for endoscopic intervention, and the discriminative performance for predicting the most important outcome, mortality, is relatively poor6,7. Furthermore, although these scoring systems could be mainly applied to patients
with UGIB, scoring systems for LGIB are relatively scarce. As noted in recent reports, scores that could be applied to both UGIB and LGIB at the same time would be useful for clinicians, since it may be challenging to make an accurate diagnosis of the bleeding location at presentation.

Scores that do not require data on endoscopic findings specific to UGIB (pre-endoscopic scores) could be applied to not only UGIB but also LGIB; thus, they can be used to assess the risk of all GIB patients. Indeed, although the Glasgow-Blatchford score (GBS), clinical Rockall score (cRS), and AIMS65 scores, all of which are pre-endoscopic scores, were initially designed for UGIB, some reports have indicated that these scores are also useful for the risk stratification of LGIB. Recently, a new pre-endoscopic score, the ABC score was developed for predicting mortality in patients with overall GIB early after presentation, and showed high accuracy for both UGIB and LGIB.

We have recently developed a simple prediction score, the CHAMPS score using the clinical data of 2205 subjects with UGIB, to predict in-hospital mortality based on six easily available clinical variables. The score successfully discriminated patients with UGIB who were at risk for in-hospital mortality with an AUC of 0.90 for derivation cohort, and 0.81 for the validation cohort, and had significantly higher discriminative ability than the GBS, cRS, AIMS65 score, and ABC score. In addition, the CHAMPS score can be applied to patients with UGIB, irrespective of the status of hospitalization (outpatient onset and inpatient onset), although most of the previous scores could only be applied to the outpatient status at the development of UGIB. Furthermore, since the CHAMPS score does not require endoscopic findings, the score could be applied to not only patients with UGIB but also patients with LGIB.

In this study, we retrospectively investigated whether the CHAMPS score, which was originally designed for risk stratification of UGIB, could also be useful for LGIB in comparison to the other above-mentioned scores.

**Results**

Initially, 512 patients with LGIB were identified in the two participating hospitals during the study period. Among these patients, 125 who did not require hospitalization due to mild bleeding were excluded, leaving 387 patients with LGIB as study subjects for this analysis (Fig. 1). The characteristic features of the 387 patients and comparisons between survivors and non-survivors are shown in Table 1. Based on colonoscopy and CT examination, the diagnoses of patients with LGIB were as follows: presumptive or definitive diverticular bleeding, n = 132 (34.1%); rectal ulcer, n = 72 (18.6%); ischemic colitis, n = 54 (13.9%); delayed post-polypectomy-induced bleeding, n = 23 (5.9%); hemorrhoid bleeding, n = 21 (5.4%); bleeding colonic cancer, n = 18 (4.7%); bleeding colitis, n = 13 (3.4%); telangiectasia, n = 8 (2.1%), and unknown/other, n = 32 (8.2%). Stigmata of recent hemorrhage was observed in 140 (36.2%) patients.
Overall, 39 (10.1%) patients died during the index hospitalization. Among these, only 4 (10.2%) died directly from uncontrolled bleeding, and the majority (89.8%) died from non-bleeding causes. The details of the cause of death are shown in Fig. 2. Meanwhile, 33 (8.5%) experienced re-bleeding during the index hospitalization.

The median CHAMPS score, GBS, cRS, AIMS65 score, and ABC score for each eligible patient was 1 (0–2), 5.5 (2–9), 3 (2–4), 1 (1–2), and 2 (1–5), respectively. ROCs comparing the performance of these 5 scoring systems in predicting in-hospital mortality are shown in Fig. 3. The CHAMPS score showed good performance in the prediction of in-hospital mortality in LGIB patients with an AUC (95% CI) of 0.80 (0.73–0.87). The performance of the CHAMPS score was significantly superior to the GBS (AUC 0.66, 95% CI 0.56–0.75, \( P < 0.01 \)), cRS (AUC 0.68, 95%CI 0.59–0.78, \( P < 0.01 \)), and ABC score (AUC 0.65, 95%CI 0.56–0.74, \( P < 0.001 \)), and was marginally superior to that of the AIMS65 score (AUC 0.68, 95% CI 0.57–0.79, \( P = 0.08 \)). The addition of the status of the presence or absence of rebleeding (point 1 or 0) to the CHAMPS score (CHAMPS-R score) made it numerically inferior to the original CHAMPS score with regard to its ability to predict in-hospital mortality (AUC 0.78, 95% CI 0.71–0.86) (data not shown). The CHAMPS score showed a high AUC in patients with either definite or presumptive source of LGIB with an AUC (95% CI) of 0.76 (0.67–0.86) or 0.84 (0.73–0.95), respectively. In addition, AUCs with 5 scores are shown in Supplemental Table 1 separately in patients with outpatient onset or inpatient onset.

The rate of in-hospital mortality in patients with a CHAMPS score of 0, 1, 2, 3, 4, and \( \geq 5 \) were 1.8%, 1.9%, 15.0%, 17.5%, 37.0%, and 37.5%, respectively. Thus, in-hospital mortality increased in a three-stepwise manner, and was categorized into 3 risk groups as follows: low risk (score 0 or 1), 1.8%; intermediate risk (score 2 or 3), 15.8%; and high risk (score \( \geq 4 \)), 37.1% (Table 2).

The rate of in-hospital mortality in patients with a CHAMPS score of 0, 1, 2, 3, 4, and \( \geq 5 \) were 1.8%, 1.9%, 15.0%, 17.5%, 37.0%, and 37.5%, respectively. Thus, in-hospital mortality increased in a three-stepwise manner, and was categorized into 3 risk groups as follows: low risk (score 0 or 1), 1.8%; intermediate risk (score 2 or 3), 15.8%; and high risk (score \( \geq 4 \)), 37.1% (Table 2).

The rate of in-hospital mortality in patients with a CHAMPS score of 0, 1, 2, 3, 4, and \( \geq 5 \) were 1.8%, 1.9%, 15.0%, 17.5%, 37.0%, and 37.5%, respectively. Thus, in-hospital mortality increased in a three-stepwise manner, and was categorized into 3 risk groups as follows: low risk (score 0 or 1), 1.8%; intermediate risk (score 2 or 3), 15.8%; and high risk (score \( \geq 4 \)), 37.1% (Table 2).

The rate of in-hospital mortality in patients with a CHAMPS score of 0, 1, 2, 3, 4, and \( \geq 5 \) were 1.8%, 1.9%, 15.0%, 17.5%, 37.0%, and 37.5%, respectively. Thus, in-hospital mortality increased in a three-stepwise manner, and was categorized into 3 risk groups as follows: low risk (score 0 or 1), 1.8%; intermediate risk (score 2 or 3), 15.8%; and high risk (score \( \geq 4 \)), 37.1% (Table 2).

### Table 1. Characteristics of enrolled subjects with lower gastrointestinal bleeding. Continuous variables were expressed in the median and interquartile range, and categorical valuables were expressed as the number and proportion. †: there are some cases with missing values. ECOG-PS: Eastern Cooperative Oncology Group Performance Status; INR: International normalized ratio; BUN: Blood urea nitrogen.

|                      | Total (n = 387) | Survival (n = 348) | Death (n = 39) | \( P \) value |
|----------------------|----------------|-------------------|---------------|--------------|
| Sex: male            | 223 (57.6%)    | 195 (56.0%)       | 28 (71.8%)    | 0.054        |
| Age: years           | 75 (64–83)     | 71.5 (63–82)      | 75.8 (64–87)  | 0.078        |
| In-hospital onset    | 106 (27.4%)    | 80 (23.0%)        | 26 (66.7%)    | <.00001      |
| ECOG-PS              | 1 (0–2)        | 1 (0–2)           | 2 (1–4)       | <.0001       |
| Charlson Comorbidity Index | 2 (0–3)   | 2 (0–3)           | 3 (2–5)       | 0.0001       |
| Altered mental status | 20 (5.2%)     | 18 (5.2%)         | 2 (5.1%)      | 1.0          |
| Systolic blood pressure: mmHg (n = 384)† | 125 (106–142)      | 125.7 (108–144)       | 109 (96.7–122)     | <.0001       |
| Heart rate: mminn. (n = 384)† | 81 (70–95)   | 82.6 (70–95)      | 86.4 (72–99)  | 0.20         |
| Blood test           |                |                   |               |              |
| Hemoglobin: g/dl     | 11 (8.7–13.2)  | 11.0 (8.9–13.3)   | 9.4 (7.3–11)  | 0.001        |
| Serum Albumin: g/dl (n = 371)† | 3.4 (2.9–4.0)          | 3.5 (3–4)         | 2.4 (1.9–3)  | <.00001      |
| INR (n = 308)†       | 1.06 (0.96–1.3) | 1.3 (0.9–1.2)     | 1.3 (1.1–1.5) | 0.84         |
| BUN: mg/dl (n = 378)† | 19.0 (13.8–28.7)          | 23.3 (13.7–28.2)  | 31.9 (15.7–41.9) | 0.0044      |
| Creatinine: mg/dl (n = 376)† | 0.8 (0.6–1.1)           | 1.1 (0.6–1.1)     | 1.5 (0.7–1.7) | 0.074        |
| Medication           |                |                   |               |              |
| Non-steroidal anti-inflammatory drugs: yes | 60 (15.5%)   | 50 (14.7%)        | 10 (25.6%)    | 0.098        |
| Anti-thrombotics: yes | 82 (21.2%)        | 71(20.4%)         | 11 (28.2%)    | 0.30         |
| Steroid: yes         | 36 (9.3%)       | 30 (8.6%)         | 6 (15.4%)     | 0.24         |
| Stigma of recent hemorrhage: yes | 140 (36.2%)          | 123 (35.3%)       | 17 (43.6%)    | 0.38         |
| Re-bleeding: yes     | 33 (8.5%)       | 30 (8.6%)         | 3 (7.7%)      | 1.0          |
| Emergency CT: yes    | 104 (26.9%)     | 99 (28.4%)        | 5 (12.8%)     | 0.037        |
| Scoring system       |                |                   |               |              |
| CHAMPS score (n = 372)† | 1 (0–2)           | 1 (0–2)           | 3 (2–4)       | <.0001       |
| Glasgow-Blatchford score (n = 374)† | 5.5 (2–9)            | 1 (1–2)           | 2 (1–3)       | 0.0001       |
| Clinical Rockall score (n = 384)† | 3 (2–4)            | 3 (1–4)           | 4 (2–5)       | <.0001       |
| AIMS65 score (n = 307)† | 1 (1–2)           | 2 (2–9)           | 8 (5–11)      | 0.0011       |
| ABC score (n = 376)†  | 2 (1–5)         | 2 (1–5)           | 4 (2–7)       | 0.0052       |
Figure 2. Causes of death in 39 cases with a fatal outcome.

Figure 3. Receiver operating characteristic curves comparing the performance of the five scoring systems in the prediction of in-hospital mortality. AUC, area under the receiver operating characteristic curve; CI, confidence interval; cRS, clinical Rockall score; GBS, Glasgow-Blatchford score.
52.8% sensitivity and 69.9% specificity with an overall accuracy of 68.3%. Thus, among the 5 investigated scoring systems, the CHAMPS score showed the highest overall accuracy in predicting high-risk patients.

The ROCs to compare the performance of the CHAMPS score, GBS, cRS, AIMS65 score, and ABC score in predicting rebleeding are shown in Supplemental Fig. 1. The CHAMPS score showed only modest performance in predicting rebleeding in LGIB patients with an AUC (95% CI) of 0.67 (0.57–0.77); the other 4 scoring systems showed similarly modest performance with AUCs ranging from 0.57 to 0.67 (Supplemental Fig. 1).

Discussion

We recently developed a simple, pre-endoscopic score (CHAMPS score) with high discriminative ability for predicting in-hospital mortality in patients with UGIB14. Furthermore, the current study demonstrated that the CHAMPS score also has high discriminative ability (AUC: 0.80) for predicting in-hospital mortality in patients with LGIB, with a significantly higher AUC in comparison to the other existing scores. Thus, the CHAMPS score should be useful for the earlier prediction of the most important outcome, death, in all patients with GIB.

In this study, the rate of all-cause in-hospital mortality in patients with LGIB was 10.1%, which was substantially higher than that in previous studies (3–4%)3,5,6,17. The exclusion of mild LGIB, which was not required for hospitalization, should be partly responsible for the higher in-hospital mortality observed in this study. Alternatively, this study included cases of both outpatient- and inpatient-onset LGIB, while many previous studies only included outpatient-onset LGIB. This could be another reason for the high mortality in this study.

Table 2. Distribution of risk scores and risk classification in CHAMPS score for in-hospital mortality in patients with lower gastrointestinal bleeding. † There were missing data in 15 cases. CI, confidence interval.

Table 3. Comparison of diagnostic ability for in-hospital mortality among five prediction scores in patients with lower gastrointestinal bleeding. AUC area under the receiver operating characteristic curve, GBS Glasgow Blatchford score, cRS clinical Rockall score, CI confidence interval, PPV positive predictive value, NPV negative predictive value. † Low-risk, CHAMPS scores = 0, 1; GBS ≤ 1; cRS = 0; AIMS65 score ≤ 1; and ABC score ≤ 3. ‡ High-risk, CHAMPS scores ≥ 4; GBS ≥ 5; cRS ≥ 3; AIMS65 score ≥ 2; and ABC score ≥ 8.
The threshold for low-risk patients was set at 0, while that for high-risk patients was set at ≥ 314. Nonetheless, the range of GIB patients, irrespective of the bleeding source (UGIB or LGIB) or hospitalization status (outpatient or inpatient), was investigated (3.0–16.4%). For these patients, although they required hospitalization for LGIB, early discharge could be possible. On the other hand, 9.4% were categorized as high-risk. These patients showed a very high rate (37.1%) of in-hospital mortality, which was much higher than that of the other 4 scores (12.9–16.4%). Since approximately 90% of this group died from the non-bleeding related causes, systematic, intensive care in a specialized unit from the initial stage would be appropriate. Meanwhile, although the remaining 32% of patients were categorized as intermediate-risk, the in-hospital mortality rate was substantial (15.8%); hence, early discharge should be avoided and careful observation is required for these patients. Thus, the CHAMPS score should be useful for the management of LGIB patients depending on their degree of risk at presentation.

GIB can be a life-threatening condition and requires emergent testing and treatment, irrespective of the source of bleeding. Although some different treatment approaches could be applied depending on the source of bleeding (UGIB or LGIB), it is not always easy to distinguish between UGIB and LGIB in patients with haematochezia, especially at presentation. Hence, a scoring system to predict significant outcomes irrespective of the source of bleeding would be useful in considering the initial response of patients with GIB8,9. In the present study, we demonstrated that the CHAMPS score is useful for predicting the most important outcome, mortality, in a broad range of GIB patients, irrespective of the bleeding source (UGIB or LGIB) or hospitalization status (outpatient onset or inpatient onset).

In our original study to develop the CHAMPS score for predicting in-hospital mortality in patients with UGIB, the threshold for low-risk patients was set at 0, while that for high-risk patients was set at ≥ 314. Nonetheless, in the current study, which analyzed patients with LGIB, the risk of in-hospital mortality increased in a three-stepwise manner as the CHAMPS score increased, and the patients could be categorized into 3 groups accordingly. Then, we modified the thresholds for predicting in-hospital mortality in patients with LGIB, changing the threshold for low-risk to ≤ 1 and that for high-risk to ≥ 4. Actually, the overall accuracy in predicting low-risk and high-risk patients with the modified thresholds of the CHAMPS score seems to be superior to that of the original thresholds (Supplemental Table 2). Although the CHAMPS score itself is useful for predicting in-hospital mortality, irrespective of the source of GIB (UGIB or LGIB), further studies are warranted to investigate whether different thresholds are required for risk stratification between UGIB and LGIB.

The ABC score has recently been developed to predict mortality in both UGIB and LGIB among European populations, and showed good performance in UGIB (AUC: 0.86 and 0.81) and LGIB (AUC: 0.84)9. Nonetheless, the ABC score showed rather low performance in the Japanese population in our recent study dealing with UGIB (AUC = 0.77)14 and in the current study dealing with LGIB (AUC = 0.65). The discordant performance of the ABC may be partly explained by the ethnic difference (European population vs. Japanese population), as patient age is a significant risk factor for mortality in the former but not in the latter14,13. Otherwise, the potential difference in the underlying diseases of GIB between the two populations may be responsible for the discordant performance. In particular, acute hemorrhagic rectal ulcers, which are much more common in Asian countries and which are associated with a poor prognosis11,22, accounted for a substantial portion (19%) of the enrolled LGIB in the current study.

Recently, a risk scoring system (NOBLADS score) was developed to predict severe outcomes (e.g., rebleeding, blood transfusion, longer hospital stay, and intervention) in Japanese subjects with LGIB12. Nonetheless, the additional analysis revealed that the CHAMPS score showed significantly higher discriminatory ability in the prediction of in-hospital mortality in comparison to the NOBLADS score (AUC [95%CI]: CHAMPS, 0.80 [0.73–0.87]; NOBLADS, 0.73 [0.65–0.81]; P = 0.02, Supplemental Fig. 2). In addition, although the CHAMPS score was already validated for UGIB, the NOBLADS is unsuitable for predicting the outcomes of GIB since some of the factors evaluated in the system should apply specifically to patients with LGIB (e.g., diarrhea and abdominal tenderness)33. Thus, the CHAMPS score is superior to the NOBLADS score as a single scoring system to predict in-hospital mortality for UGIB and LGIB together.

One limitation of this study may be the relatively low number of enrolled patients. Although clinical data on consecutive patients with LGIB who were managed at two tertiary academic medical centers over a 6-year period were collected with a substantial number of cases with the main outcome (in-hospital mortality), the number of subjects may have been insufficient to draw robust conclusions. Furthermore, several variables, especially INR, had missing values, and we had to exclude those cases from the analysis. Finally, in the current study dealing with LGIB, there were no significant differences in altered mental status or steroid use between survivors and non-survivors, although these two factors were incorporated into the CHAMPS score based on our recent study dealing with UGIB14. In this study, we would prioritize applying the same scoring system (CHAMPS score) to both UGIB and LGIB, rather than establishing a different, new score for LIBG alone. Nonetheless, these two factors may not necessarily be required to predict the mortality in LGIB, and indeed, the AUC remained high, even after excluding the two factors from the scoring system (AUC [95%CI]: 0.81 [0.73–0.88]) (data not shown). An additional study is required to further validate the usefulness of the CHAMPS score in the risk stratification of patients with LGIB.
Conclusion
This study successfully demonstrated that the CHAMPS score, a score originally developed for UGIB, is also useful for predicting in-hospital mortality in patients with LGIB. Thus, the CHAMPS may be useful for risk stratification at presentation in all patients with signs of suspected GIB (e.g., hematemesis, hematochezia, and anemia) irrespective of the source of bleeding.

Methods
Patients. Consecutive adult patients who were hospitalized with LGIB from 2015 to 2020 at two tertiary academic medical centers in Akita prefecture in Japan (Akita University Hospital and Akita City Hospital) were retrospectively enrolled in this study. Those with mild LGIB, who did not require hospitalization, were excluded since the main outcome of this study was in-hospital mortality. Patients with hospitalization for LGIB (outpatient onset) or the development of LGIB after hospitalization for another indication (inpatient onset) were both included in the analysis. The indications for hospitalization were clinically significant GIB (e.g., hypotension, shock, orthostatic changes in systolic blood pressure and/or pulse, repeated bleeding, or a > 2 g decrease in hemoglobin from baseline).

Data collection. The following clinical data, which are required to calculate the CHAMPS score, GBS, cRS, AIMS65 score, and ABC score, were collected3–6,9,14: patient demographics (age and sex), in-hospital/out-of-hospital onset, altered mental status, vital signs (systolic blood pressure and pulse), physical condition (Eastern Cooperative Oncology Group performance status), comorbid conditions (Charlson Comorbidity Index), blood test (hemoglobin, albumin, and creatinine, international normalized ratio [INR], and blood urea nitrogen [BUN]), and medication (anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, and steroids) at the onset of LGIB.

Data availability. The datasets used and analyzed during the current study available from the corresponding author on reasonable request.

CHAMPS score. The CHAMPS score is a simple equal-weight score, determined based on six variables (Charlson Comorbidity Index ≥ 2, in-hospital onset, albumin < 2.5 g/dL, altered mental status, Eastern Cooperative Oncology Group performance status ≥ 2, steroid use); the maximum score is six points (Table 4)14.

Definitions. LGIB was defined as presentation with hematochezia, including red blood or clots per rectum, maroon-colored stool or blood mixed in with stool, but any patient with suspected UGIB at esophagogastroduodenoscopy was excluded. Colonoscopy was performed emergently or electively with or without CT in all patients with LGIB to identify the source of bleeding. Both definite and presumptive sources of LGIB were included. Definite sources of bleeding were defined as lesions with documented visualization of active bleeding, a visible vessel, or adherent clot (stigmata of recent hemorrhage)24. Presumptive diagnoses were defined as cases of diverticula, hemorrhoids, or angiodysplasia, without stigmata of recent bleeding24.

Outcomes. The primary outcome of this study was the usefulness of the CHAMPS score for predicting in-hospital mortality in patients with LGIB. This was determined by comparing the CHAMPS score with existing scoring systems. In-hospital mortality was defined as death during the index hospitalization, whatever the cause. The secondary outcome was the efficacy of the CHAMPS score for predicting re-bleeding during the index hospitalization. Re-bleeding was suspected based on the presence of fresh hematochezia and circulating instability after successful hemostasis and was defined as a new bleeding episode from the same source based on an endoscopic examination.

Ethical considerations. The protocol for this study was approved by the ethics committee of Akita University School of the Medicine (approval number: 2676). All the methods were performed in accordance with relevant guidelines and regulations. The relevant informed consent was obtained from patients enrolled and the study design was published, and patients had a chance to opt out of the use of their information for this study.

| Variables | Points |
|-----------|--------|
| Charlson Comorbidity Index (≥ 2) | 1 |
| In-hospital onset (Yes) | 1 |
| Albumin (< 2.5 g/dL) | 1 |
| Altered mental status (Yes) | 1 |
| Eastern Cooperative Oncology Group Performance Status (≥ 2) | 1 |
| Steroids (Yes) | 1 |
| Total | 6 |

Table 4. CHAMPS score comprising equal-weight six variables.
Statistical analyses. Continuous variables were expressed as the median and interquartile range and were compared using the Mann–Whitney U-test. Categorical valuables were expressed as the number and proportion and were compared using the chi-squared test. The performance of the scoring systems for predicting outcomes was assessed by a receiver operating characteristic curve (ROC) analysis. The area under the receiver operating characteristic curve (AUC) was calculated, and the CHAMPS score was compared with those of four existing scores (GBS, cRS, AIMS65 score, and ABC Score) using the DeLong test. Then, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of each score were compared. According to the previous studies, the thresholds for low-risk patients were set at ≤ 1, 0, ≤ 1, and ≤ 3 in the GBS, cRS, AIMS65 score, and ABC score, respectively, while those for high-risk patients were set at ≥ 5, ≥ 2, ≥ 2, and ≥ 8. All analyses were conducted using the EZR software program (Saitama Medical Center, Jichi Medical University, Saitama, Japan), and P values of < 0.05 were considered to indicate statistical significance.

Received: 8 March 2022; Accepted: 25 April 2022
Published online: 09 May 2022

References
1. Sung, J. J. et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am. J. Gastroenterol. 105, 84–89 (2010).
2. Oakland, K. et al. UK lower GI bleeding collaborative. Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit. Gut 67, 654–662 (2018).
3. Blatchford, O., Murray, W. R. & Blatchford, M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 356, 1318–1321 (2000).
4. Rockall, T. A., Logan, R. F., Devlin, H. B. & Northfield, T. C. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National audit of acute upper gastrointestinal haemorrhage. Lancet 347, 1138–40 (1996).
5. Saltzman, J. R. et al. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest. Endosc. 74, 1215–1224 (2011).
6. Stanley, A. J. et al. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ 356, i6432 (2017).
7. Oakland, K. Risk stratification in upper and lower GI bleeding: which scores should we use?. Best Pract. Res. Clin. Gastroenterol. 42–43, 101613 (2019).
8. Time to Get Control. A review of the care received by patients who had a severe gastrointestinal haemorrhage. UK: NCEPOD, 2015.
9. Laursen, S. B. et al. ABC score: a new risk score that accurately predicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study. Gut 70, 707–716 (2021).
10. Ur-Rahman, A. et al. Both full Glasgow-Blatchford score and modified Glasgow-Blatchford score predict the need for intervention and mortality in patients with acute lower gastrointestinal bleeding. Dig. Dis. Sci. 63, 3020–3025 (2018).
11. Tapaskar, N., Jones, B., Mei, S. & Sengupta, N. Comparison of clinical prediction tools and identification of risk factors for adverse outcomes in acute lower GI bleeding. Gastrointest. Endosc. 89, 1005–1013.e2 (2019).
12. Fujita, M. et al. Differences in emergency endoscopy outcomes according to gastrointestinal bleeding location. Scand. J Gastroenterol. 56, 86–93 (2021).
13. Nakamura, S. et al. Emergency endoscopy for acute gastrointestinal bleeding: prognostic value of endoscopic hemostasis and the AIMS65 score in Japanese patients. Dig. Endosc. 26, 369–376 (2014).
14. Matsuhashi, T. et al. A simple prediction score for in-hospital mortality in patients with nonvariceal upper gastrointestinal bleeding. J. Gastroenterol. 56, 758–768 (2021).
15. Matsuhashi, T. et al. Effects of anti-thrombotic drugs on all-cause mortality after upper gastrointestinal bleeding in Japan: a multicenter study with 2205 cases. Dig. Endosc. 34, 113–122 (2022).
16. Longstreth, G. F. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am. J. Gastroenterol. 92, 419–424 (1997).
17. Strate, L. L., Ayanian, J. Z., Kotler, G. & Syngal, S. Risk factors for mortality in lower intestinal bleeding. Clin. Gastroenterol. Hepatol. 6, 1004–1010 (2008).
18. Akirov, A. et al. Low Albumin levels are associated with mortality risk in hospitalized patients. Am. J. Med. 130, e1411–e1419 (2017).
19. Marmo, R. et al. Predictive factors of mortality from nonvariceal upper gastrointestinal hemorrhage: a multicenter study. Am. J. Gastroenterol. 103, 1639–1647 (2008).
20. Matsuhashi, T. et al. Nature and treatment outcomes of bleeding post-bulbar duodenal ulcers. Dig. Endosc. https://doi.org/10.1111/den.14160 (2021).
21. Motomura, Y. et al. Clinical and endoscopic characteristics of acute haemorrhagic rectal ulcer, and endoscopic haemostatic treatment: a retrospective study of 95 patients. Colorectal Dis. 12, e320–e325 (2010).
22. Sugawa, C. et al. Acute hemorrhagic rectal ulcer: Experience in 11 patients at an urban acute care center in the USA: a case series. Medicine (Baltimore) 99, e19836 (2020).
23. Aoki, T. et al. Development and validation of a risk scoring system for severe acute lower gastrointestinal bleeding. Clin. Gastroenterol. Hepatol. 14, 1562–1570 (2016).
24. Nagata, N. et al. Guidelines for colonic diverticular bleeding and colonic diverticulitis: Japan Gastroenterological Association. Digestion 99(Suppl 1), 1–26 (2019).
25. Hyett, B. H. et al. The AIMS65 score compared with the Glasgow-Blatchford Score in predicting outcomes in upper GI bleeding. Gastrointest. Endosc. 77, 551–557 (2013).
26. Kanda, Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 48, 452–458 (2013).

Author contributions
Study concept and design: K.I. Statistical analysis: M.T., T.M. Recruitment of participants and acquisition of data: M.T., T.M., Y. S., S.F., T.T., K.S., Y.S., Y.T., K.W., K.I. Drafting of the manuscript: M.T. Approval of final manuscript: all authors.
**Funding**
K. I. received lecture fees from Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and received Commercial research funding from Otsuka Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd.

**Competing interests**
The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-11666-y.

**Correspondence** and requests for materials should be addressed to Y.S.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022